NIH Center for Cancer Research: Clinical Trial Researching Combination Drug Therapy for Neuroendocrine Carcinomas
January 15, 2025
January 15, 2025
BETHESDA, Maryland, Jan. 15 (TNSres) -- The National Institutes of Health Center for Cancer Research issued the following news:
High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with two other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the . . .
High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with two other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the . . .